FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3692758017 | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692760015 | Benzocaine 20 mg/g and salicylamide 50 mg/g cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 471047011 | Benzocaine+salicylamide 2%/5% gel | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 471047011 | Benzocaine+salicylamide 2%/5% gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 725049014 | Benzocaine+salicylamide 2%/5% gel (substance) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1193804019 | Benzocaine+salicylamide 2%/5% gel (product) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1193804019 | Benzocaine+salicylamide 2%/5% gel (product) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692758017 | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692759013 | Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3692760015 | Benzocaine 20 mg/g and salicylamide 50 mg/g cutaneous gel | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing benzocaine (medicinal product) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Benzocaine | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Benzocaine- and salicylamide-containing product | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | forme pharmaceutique pour usage transdermique et/ou cutané | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Salicylamide | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Gel (basic dose form) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has manufactured dose form | Conventional release cutaneous gel (dose form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Product containing benzocaine in topical dosage form | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Count of base of active ingredient | deux | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator unit (attribute) | g | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator unit | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator unit | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength denominator unit (attribute) | g | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Salicylamide | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 20 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Benzocaine | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Benzocaine | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has concentration strength numerator value | 50 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Is a | Benzocaine and salicylamide only product in cutaneous dose form | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Salicylamide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has basis of strength substance (attribute) | Benzocaine | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Benzocaine | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
| Product containing precisely benzocaine 20 milligram/1 gram and salicylamide 50 milligram/1 gram conventional release cutaneous gel (clinical drug) | Has precise active ingredient | Salicylamide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets